Join our community of smart investors

Hikma builds its injectables pipeline

A $300m buyback is in the works
Hikma builds its injectables pipeline

 

  • Revenues up across all three business segments
  • Increased capabilities in the injectables space

Hikma Pharmaceuticals (HIK) delivered a 12 per cent increase in core operating profit through 2021 on the back of an increase in the generics margin, up 300-basis points to 24.36 per cent at the operating level. Statutory earnings decreased marginally, though revenues were up across all three business segments and the group expanded its specialty product offering in the US.

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in